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Abstract 
Background: Schizophrenia is one of the leading public health issues in psychiatry and imposes a heavy financial 
burden on the healthcare systems. This study aims to report the direct medical costs and the associated factors for 
patients with schizophrenia in Guangzhou city, Southern China.
Methods: This was a retrospective 4-year cohort study. Data were obtained from urban health insurance claims data-
bases of Guangzhou city, which contains patients’ sociodemographic characteristics, direct medical costs of inpatient 
and outpatient care. The study cohort (including all the reimbursement claims submitted for schizophrenia inpatient 
care during November 2010 and October 2014) was identified using the International Classification of Diseases Tenth 
version (F20). Their outpatient care information was merged from outpatient claims database. Descriptive analysis and 
the multivariate regression analysis based on Generalized Estimating Equations model were conducted.
Results: A total of 2971 patients were identified in the baseline. The cohort had a mean age of 50.3 years old, 60.6% 
were male, and 67.0% received medical treatment in the tertiary hospitals. The average annual length of stay was 
254.7 days. The average annual total direct medical costs per patient was 41,972.4 Chinese Yuan (CNY) ($6852.5). The 
inpatient costs remained as the key component of total medical costs. The Urban Employee Basic Medical Insurance 
enrollees with schizophrenia had higher average costs for hospitalization (CNY42,375.1) than the Urban Resident Basic 
Medical Insurance enrollees (CNY40,917.3), and had higher reimbursement rate (85.8% and 61.5%). The non-medi-
cation treatment costs accounted for the biggest proportion of inpatient costs for both schemes (55.8% and 64.7%). 
Regression analysis suggested that insurance type, age, hospital levels, and length of stay were significantly associated 
with inpatient costs of schizophrenia.
Conclusions: The direct annual medical costs of schizophrenia were high and varied by types of insurance in urban 
China. The findings of this study provide vital information to understand the burden of schizophrenia in China. Results 
of this study can help decision-makers assess the financial impact of schizophrenia.
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Introduction
Schizophrenia is one of the leading public health issues in 
psychiatry and is ranked among the top 25 leading causes 
of disability worldwide [1, 2]. A meta-analysis study 
estimated the worldwide prevalence of schizophrenia 
to be 0.54% [3]. In China, a large-scale study estimated 
a 1-month prevalence rate of 0.78%, with similar rates 
found in rural (0.80%) and urban (0.72%) areas [4].
Schizophrenia imposed a heavy financial burden on the 
healthcare systems. A review of cost-of-illness studies for 
schizophrenia worldwide reported that the direct medi-
cal costs of treating schizophrenia accounted for between 
1.4 and 3.0% of total national health expenditures [5]. The 
economic burden of schizophrenia was found to be more 
than US$60 billion per year in the United States [6]. In 
China, schizophrenia has been reported to contribute 
1.3% of the total burden of disease [7]. The tremendous 
changes in insurance coverage implemented in the last 
decade have the potential to improve access to effective 
health care for patients with schizophrenia and to poten-
tially reduce health-related disability [7].
China expands health insurance coverage to all urban 
residents with two social health insurance schemes—
the Urban Employee Basic Medical Insurance (UEBMI; 
launched in 1998) and the Urban Resident Basic Medi-
cal Insurance (URBMI; launched in 2007) [8]. The 
UEBMI (which mainly covers the urban employees) 
and the URBMI (which covers the urban non-employed 
residents) have different sources of funding, and offered 
enrollees different benefit packages and levels of finan-
cial protection [8]. Except for above two social health 
insurance schemes, the Chinese government has also 
implemented a government-funded Medical Care Aid 
program, which provides additional subsidies for lower 
income enrollees with specific disease such as schizo-
phrenia [9], so as to reduce the out-of-pocket (OOP) 
costs for patients from the poorest households. Criti-
cal information regarding the per-person annual direct 
medical costs associated with schizophrenia is needed for 
health care planning and financing.
Previous studies have evaluated the economic bur-
den and direct medical costs of schizophrenia mostly in 
developed countries [10–14] and occasionally in devel-
oping countries [15, 16], suggesting a large variation in 
costs across the international cost-of-illness studies for 
schizophrenia. In the United States, Cloutier et  al. [10] 
used a retrospective cohort and MarketScan Commercial 
Claims database to assess the direct health care costs of 
schizophrenia. This study found that the annual direct 
health care costs per commercially-insured patient with 
schizophrenia were US$18,090 in 2013 [10]. Another 
US study using the same claims database found that 
the mean cost per patient per month for a patient with 
schizophrenia was US$1806 (US$21,672 yearly) in 2011 
[13]. In Germany, Frey [11] used a retrospective cohort 
and sickness fund claims database to investigate the 
burden of schizophrenia. Their results showed that the 
annual cost attributable to schizophrenia was €12,251 
per patient from the payers’ perspective in 2008 [11]. 
Another Germany study used health insurance claims 
data to examine the cost of schizophrenia and predic-
tors of hospitalization [14]. They reported that the mean 
costs of stable and unstable patients with schizophrenia 
were €1605 and €12,864 respectively in 2006 [14]. In 
Switzerland, Pletscher et  al. [12] combined the health 
insurance claims data with outpatient physician survey 
to estimate the cost of schizophrenia, and found that the 
direct medical costs per patient were €9507 in 2012. In 
addition, there are limited studies that have examined the 
direct medical costs of schizophrenia in low- and middle-
income countries. In Malaysia, Teoh et al. [15] used the 
data source from medical chart review and suggested 
that the mean cost per patient was US$6594 in 2015. In 
Indian, Grover et  al. [16] assessed the cost of care for 
schizophrenia through interview and questionnaires col-
lected from outpatients only, and found that the annual 
direct medical costs of care was US$274. As found by a 
systematic review, claims databases were the most com-
monly used data sources in most direct medical cost esti-
mation for schizophrenia in the high-income countries, 
while chart review and interview were the main data 
sources used in low and middle-income countries [17].
Only a few studies examined the direct medical costs 
of schizophrenia in China [18–20]. Zhai et al. [19] inves-
tigated the economic cost of schizophrenia through a 
cross-sectional survey and found that the per case annual 
direct costs of schizophrenia was US$862.81 in 2010. 
Yang et al. [20] analyzed the inpatient costs of psychiat-
ric patients including schizophrenia in Zhejiang Province 
and discovered that the median cost of hospitalization 
was US$1539 in 2010. However, these two studies had 
relatively small sample sizes and were limited to the per-
spective of one or two hospitals and hospitalized patients 
only. Wu et  al. [18] estimated the direct medical costs 
for patients with schizophrenia in Tianjin city, North-
ern China, and reported that the annual mean costs 
were US$2863 per patient in 2009. But Wu et al.’s study 
only included patients covered by one insurance scheme 
(UEBMI), and did not investigate the key drivers of inpa-
tient costs.
Different from previous literature (which either col-
lected data from a selected sample of hospitals or focused 
on patients with a particular health insurance), this study 
aims to examine the direct medical costs for patients 
with schizophrenia and the factors that were associated 
with the inpatient costs using a 4-year health insurance 
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claims data from the largest city in Southern China. The 
data in this study covers all patients who were insured 
with either of the two urban health insurance schemes.
Materials and methods
Data source
Data in this study were obtained from the UEBMI and 
URBMI claims databases of Guangzhou city for the 
years 2010 through 2014, which contained sociodemo-
graphic information, direct medical costs of inpatient 
and outpatient care based on actual payments to health 
care providers. Guangzhou city is the capital of Guang-
dong Province and is one of the most developed cit-
ies in Southern China. By 2014, 96.6% of the registered 
residents were enrolled in the two insurance schemes 
in Guangzhou city [21]. The detailed reimbursement 
policies and benefit packages of the UEBMI and URBMI 
schemes from Guangzhou city in 2014 are summarized 
in Table 1.
Study design
This was a retrospective cohort study designed to esti-
mate the direct medical costs of patients with schizophre-
nia. We obtained all the reimbursement claims submitted 
for inpatient care during November 2010 and October 
2014 using the International Classification of Diseases 
Tenth version (ICD-10) (F20). The cohort was identi-
fied using the inpatient claims database that included the 
records of all insured schizophrenia patients who were 
admitted to hospitals in Guangzhou between Novem-
ber 1, 2010 and October 31, 2011. Their outpatient 
care information was then merged from the outpatient 
claims database. Index diagnosis date for each patient 
was defined as the first observed primary diagnosis of 
schizophrenia during November 1, 2010 through Octo-
ber 31, 2011, and the baseline period was defined as the 
first 12 months following index diagnosis date. The first/
second/third follow-up year was the second/third/fourth 
12  months following index diagnosis date, respectively. 
Patients who were under 18 years old were excluded. The 
final sample included 2971 patients, including 1760 and 
1211 patients who were insured with the UEBMI and the 
URBMI, respectively.
This study adopted the Andersen’s behavioral model 
[22] as the conceptual framework to identify the predic-
tors of total inpatient costs for patients with schizophre-
nia. Individual characteristics were identified in terms 
of: (1) predisposing factors—existing conditions with 
predispose individuals to use or not use services (e.g. age 
and gender); (2) enabling factors—conditions that facili-
tate or impede the use of services (e.g. types of health 
insurance); and (3) need factors—conditions that health-
care providers recognize as requiring long-term medical 
treatment (e.g. the severity of disease, which was proxied 
by the length of stay (LOS) and hospital levels) [22].
Cost estimation
The health insurance claims databases contained infor-
mation on the actual direct total medical costs of schizo-
phrenia patients, including the reimbursement from the 
health insurance scheme (either UEBMI or URBMI), the 
co-payment from enrollees and the aid received through 
the government-funded Medical Care Aid Program that 
were only available for patients who met certain crite-
ria. The total annual direct medical cost (consisting of 
both inpatient and outpatient costs) was calculated for 
each patient. Costs of schizophrenia were annual medi-
cal costs per capita incurred in the inpatient and out-
patient sectors. All costs presented in this study were 
based on a constant 2014 Chinese Yuan (CNY), adjusted 
using the Consumer Price Index (CPI) of Guangzhou 
city [21]. According to the Bank of China, the annual 
exchange rate between US dollar and CNY in 2014 was: 
US$1.0 = CNY6.1251.
The inpatient medical costs were categorized as labo-
ratory and diagnostic costs, non-medication treatment 
costs, medication costs, and bed fees in the health insur-
ance claims database. Laboratory and diagnostic costs 
referred to the costs of physical examinations and bio-
chemical tests. Medication costs were grouped into tra-
ditional Chinese medicine and Western medicine costs. 
Non-medication treatment costs referred to the costs 
for any other treatments except for medication, which 
included blood transfusion costs, surgery fees, anesthe-
sia charges, and costs for medical consumables. Bed fees 
were the accommodation costs during hospitalization.
Information on patient characteristics (age, gender, 
type of insurance), hospital levels (primary, secondary, 
tertiary), and length of stay (LOS) was also obtained from 
the claims database.
Statistical analysis
Descriptive statistics [frequency, percentage, mean, 
and standard deviation (SD)] were calculated for demo-
graphic information and costs. Since the medical cost 
data usually has a skewed distribution, the Kruskal–Wal-
lis test was used to investigate whether the differences in 
patients’ characteristics of two health insurance schemes 
were statistically significant. To identify the predictors 
of total inpatient costs, a popular statistical approach to 
fit a marginal model for longitudinal data, the General-
ized Estimating Equations (GEE) model (specified with 
gamma family, log link function and unstructured cor-
relation structure), was performed in this study [23]. All 
statistical calculations were performed using Stata ver-
sion 12.0 (Stata Corporation, College Station, TX, USA).
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Results
Patient characteristics
A total of 2971 patients were identified in the baseline 
period (Table 2). More than half of the patients were male 
(60.6%). The average age was 50.3 years old (SD = 12.7). 
Patients in the UEBMI subgroup (n = 1760) were on 
average aged 52.4  years, while patients in the URBMI 
subgroup (n = 1211) were slightly younger (47.3  years). 
Most of the patients received medical treatment in 
tertiary hospitals (67.0%), and the mean annual LOS 
was 254.7  days. For this study cohort, there were 2021 
patients in the first-year follow-up period, 1901 patients 
in the second and 1754 patients in the third follow-up 
periods respectively.
Annual total medical costs of schizophrenia
In the baseline period, the mean annual total direct med-
ical costs per patient was CNY41,972.4 (US$6852.5) and 
the vast majority was inpatient costs: mean inpatient 
costs (CNY41,780.9, US$6821.3) versus mean outpatient 
costs (CNY191.5, US$31.3) (see Table  3). On the other 
hand, the percentage of OOP expenses out of inpatient 
costs (14.3%) was much less than the OOP percentage 
out of outpatient costs (63.6%). During the 3-year follow-
up periods, the per capita total medical costs (constant 
2014 price) increased to CNY55,934.5 (US$9132.0), 
CNY55,778.4 (US$9106.5) and CNY56,544.1 
(US$9231.5), respectively. The inpatient costs remained 
as the key component of the total medical costs in the 
follow-up three periods.
When analyzing the annual medical costs by patients’ 
insurance status, the mean total medical costs for the 
UEBMI group was higher than the URBMI group during 
the baseline and 3-year follow-up periods (P < 0.05). Fur-
thermore, in the baseline period the per capita inpatient 
costs of patients with the UEBMI were higher than those 
of patients with the URBMI scheme, while the per capita 
outpatient costs of the UEBMI patients were lower than 
those of the URBMI patients (P < 0.05). The percentage 
of reimbursement expenses out of inpatient costs for the 
UEBMI scheme patients (85.8%) was much higher than 
the patients with the URBMI scheme (61.5%), because 
Table 2 Baseline patients characteristics
n(%) for categorical variables and mean ± standard deviation for continuous variables
UEBMI Urban Employee Basic Medical Insurance scheme, URBMI Urban Resident Basic Medical Insurance scheme, SD Standard deviation
Baseline (2010.11.01–2011.10.31) Overall UEBMI URBMI
No. patients n = 2971 n = 1760 n = 1211
Gender
 Female 1170.0 (39.4) 736.0 (41.8) 434.0 (35.8)
 Male 1801.0 (60.6) 1024.0 (58.2) 777.0 (64.2)
Age (years)
 Mean ± SD 50.3 ± 12.7 52.4 ± 11.8 47.3 ± 13.5
Age group
 18 ≤ age < 30 187.0 (6.3) 66.0 (3.8) 121.0 (10.0)
 30 ≤ age < 40 379.0 (12.8) 168.0 (9.5) 211.0 (17.4)
 40 ≤ age < 50 847.0 (28.5) 445.0 (25.3) 402.0 (33.2)
 50 ≤ age < 60 887.0 (29.9) 625.0 (35.5) 262.0 (21.6)
 ≥ 60 671.0 (22.6) 456.0 (25.9) 215.0 (17.8)
Hospital level
 Primary 76.0 (2.6) 45.0 (2.6) 31.0 (2.6)
 Secondary 905.0 (30.5) 517.0 (29.4) 388.0 (32.0)
 Tertiary 1990.0 (67.0) 1198.0 (68.1) 792.0 (65.4)
Length of stay (days)
 Mean ± SD 254.7 ± 135.1 244.9 ± 137.9 268.9 ± 129.8
 Days ≤ 100 737.0 (24.8) 482.0 (27.4) 255.0 (21.1)
 100 < days ≤ 300 501.0 (16.9) 315.0 (17.9) 186.0 (15.4)
 > 300 days 1733.0 (58.3) 963.0 (54.7) 770.0 (63.6)
Follow-up no. patients
 First year (2011.11.01–2012.10.31) 2021 1145 876
 Second year (2012.11.01–2013.10.31) 1901 1079 822
 Third year (2013.11.01–2014.10.31) 1754 988 766
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Table 3 Annual direct medical costs per patient by insurance type (Four Periods)
Baseline Overall UEBMI URBMI P-value
n = 2971 n = 1760 n = 1211
Total costs
 Mean (CNY) 41,972.4 42,543.1 41,143.0 0.021
 SD (CNY) 22,741.3 24,250.8 20,330.0
 Out-of-pocket (%) 13.0% 12.7% 13.5%
Inpatient costs n = 2971 n = 1760 n = 1211
 Mean (CNY) 41,780.9 42,375.1 40,917.3 0.018
 SD (CNY) 22,909.3 24,390.3 20,547.0
 Out-of-pocket (%) 14.3% 14.0% 14.7%
 Reimbursement (%) 76.1% 85.8% 61.5%
 Aid (%) 9.6% 0.2% 23.8%
Outpatient costs n = 329 n = 216 n = 113
 Mean (CNY) 191.5 168.0 225.7 0.031
 SD (CNY) 747.5 607.2 913.0
 Out-of-pocket (%) 63.6% 53.9% 74.1%
 Reimbursement (%) 36.4% 46.1% 25.9%
Follow-up: first year Overall UEBMI URBMI P-value
n = 2021 n = 1145 n = 876
Total costs
 Mean (CNY) 55,934.5 57,369.7 54,058.6 < 0.001
 SD (CNY) 19,779.9 21,320.6 17,397.7
 Out-of-pocket (%) 12.3% 10.7% 14.5%
Inpatient costs n = 2021 n = 1145 n = 876
 Mean (CNY) 55,887.6 57,332.8 53,998.5 < 0.001
 SD (CNY) 19,851.0 21,376.4 17,492.4
 Out-of-pocket (%) 12.9% 11.2% 15.2%
 Reimbursement (%) 77.6% 88.8% 62.1%
 Aid (%) 9.5% 0.0% 22.7%
Outpatient costs n = 69 n = 41 n = 28
 Mean (CNY) 47.0 36.9 60.1 0.676
SD (CNY) 339.7 273.3 410.5
Out-of-pocket (%) 67.0% 55.5% 76.4%
Reimbursement (%) 32.9% 44.6% 23.6%
Follow-up: second year Overall UEBMI URBMI P-value
n = 1901 n = 1079 n = 822
Total costs
 Mean (CNY) 55,778.4 57,326.6 53,746.0 < 0.001
 SD (CNY) 18,646.0 20,107.1 16,323.7
 Out-of-pocket (%) 8.7% 10.7% 5.9%
Inpatient costs n = 1901 n = 1079 n = 822
 Mean (CNY) 55,732.3 57,287.6 53,690.7 < 0.001
 SD (CNY) 18,725.5 20,178.4 16,416.4
 Out-of-pocket (%) 8.7% 10.7% 5.9%
 Reimbursement (%) 77.7% 88.9% 62.1%
 Aid (%) 13.6% 0.4% 32.0%
Outpatient costs n = 44 n = 22 n = 22
 Mean (CNY) 46.1 39.0 55.3 0.356
 SD (CNY) 379.8 360.5 403.8
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these two insurance schemes had different benefit pack-
ages as indicated in Table 1. However, the percentage of 
government medical aid expenses out of the inpatient 
costs for the UEBMI patients (0.2%) was much lower 
than the URBMI patients (23.8%), since most of the 
poor people who were eligible for the Medical Care Aid 
Program were enrolled under the URBMI scheme. Dur-
ing the 3-year follow-up periods, the UEBMI scheme 
patients consistently had higher reimbursement rate, 
while the URBMI patients always had higher government 
aid rate, and the percentage of government medical care 
aid expenses increased annually for both schemes.
Differences in patients who used inpatient care 
only and patients who used both inpatient and outpatient 
care
Among 2971 total patients, there were 2642 schizophre-
nia patients who used inpatient care only and 329 patients 
who used both inpatient and outpatient care in the base-
line period (see Table  4). The annual total direct medi-
cal costs between the patients who used inpatient care 
only and those who used both inpatient and outpatient 
care significantly differed according to gender, age group, 
hospital levels, LOS, and composition (all P < 0.001). The 
mean total costs for schizophrenia patients who had used 
inpatient care only (CNY44,144.6) were two times higher 
than those with both inpatient and outpatient services 
(CNY24,529.1) (P < 0.01).
Inpatient costs of schizophrenia and composition
In the baseline period, inpatient costs between the 
UEBMI subgroup and URBMI subgroup significantly 
differed according to gender, age group, hospital levels, 
LOS, and composition (all P < 0.001) (see Table  5). The 
mean inpatient costs for schizophrenia patients with the 
UEBMI (CNY42,375.1) were higher than patients with 
the URBMI scheme (CNY40,917.3) (Fig.  1). Regard-
ing cost composition, the non-medication treatment 
costs accounted for the biggest proportion of total inpa-
tient costs for both UEBMI (55.8%) and URBMI (64.7%) 
schemes. However, the smallest cost component in the 
UEBMI group was medication costs (11.0%), while the 
smallest cost component in the URBMI group was labo-
ratory and diagnostic costs (7.2%). During the 3-year fol-
low-up periods, the composition of annual total medical 
cost remain similar as the baseline period.
Predictors of inpatient costs
Table  6 shows factors associated with total annual 
inpatient costs. Regarding the full sample, this study 
found that insurance type, age, hospital levels, and 
LOS were significantly associated with inpatient costs 
P-values are based on the Mann–Whitney test. All costs were based on a constant 2014 Chinese Yuan (CNY)
UEBMI Urban Employee Basic Medical Insurance scheme, URBMI Urban Resident Basic Medical Insurance scheme, SD standard deviation
Table 3 (continued)
Follow-up: second year Overall UEBMI URBMI P-value
n = 1901 n = 1079 n = 822
 Out-of-pocket (%) 68.6% 58.1% 78.4%
 Reimbursement (%) 31.3% 41.9% 21.6%
Follow-up: third year Overall UEBMI URBMI P-value
n = 1754 n = 988 n = 766
Total costs
 Mean (CNY) 56,544.1 60,163.7 51,875.6 < 0.001
 SD (CNY) 21,283.6 22,155.4 19,130.6
 Out-of-pocket (%) 8.2% 9.5% 6.1%
Inpatient costs (n = 1229) n = 1754 n = 988 n = 766
 Mean (CNY) 56,502.7 60,145.2 51,804.5 < 0.001
 SD (CNY) 21,346.2 22,195.0 19,218.0
 Out-of-pocket (%) 8.1% 9.5% 6.0%
 Reimbursement (%) 77.6% 88.1% 61.9%
 Aid (%) 14.3% 2.4% 32.1%
Outpatient costs n = 34 n = 14 n = 20
 Mean (CNY) 41.4 18.4 71.1 0.069
 SD (CNY) 480.4 273.5 656.4
 Out-of-pocket (%) 76.6% 57.4% 83.0%
 Reimbursement (%) 23.4% 42.8% 17.0%
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of schizophrenia. Compared with patients with the 
URBMI scheme, the inpatient costs of schizophrenia 
were CNY5270.0 higher for patients with the UEBMI 
scheme (P < 0.01). There exists a non-linear relation-
ship between age and total annual inpatient costs, 
with patients aged 30–40 had the highest inpatient 
costs among all categories of age. Comparing with 
the youngest age group (18 ≤ age < 30), inpatient costs 
for patients aged 30–40 were CNY11,751.0 higher 
among the UEBMI subgroup and CNY5670.0 higher 
among the URBMI subgroup (P < 0.01). Gender was a 
significant factor only among the URBMI group, and 
male patients incurred CNY1565.8 lower inpatient 
costs than their female counterparts (P < 0.01). Inpa-
tients staying at tertiary hospitals were found to incur 
CNY30,330.8 higher inpatient costs among the UEBMI 
patients and CNY14,701.1 higher among the URBMI 
patients, compared with patients staying at primary 
hospitals (P < 0.01). For both subgroups, patients with 
longer LOS had significantly higher hospitalization 
costs. Compared with LOS less than 100  days, inpa-
tient costs for the longest LOS group (> 300  days) 
were CNY89,848.1 higher among the UEBMI patients 
and CNY84,387.9 higher among the URBMI patients 
(P < 0.01).
Table 4 Differences in patients who used inpatient care only and patients who used both inpatient and outpatient care 
(baseline period)
P-values are based on the Kruskal–Wallis test. All costs were based on a constant 2014 Chinese Yuan (CNY)
UEBMI Urban Employee Basic Medical Insurance scheme, URBMI Urban Resident Basic Medical Insurance scheme, SD standard deviation
Patients used inpatient only Patients used both inpatient 
and outpatient
P-value
Mean SD Mean SD
No. patients n = 2642 n = 329
Baseline (2010.11.01–2011.10.31)
 Gender < 0.001
  Female 40,992.4 23,387.4 24,797.1 16,566.3
  Male 46,079.8 21,526.8 24,259.4 18,365.0
 Age groups < 0.001
  18 ≤ age < 30 27,167.2 19,908.5 24,077.3 15,037.8
  30 ≤ age < 40 33,455.6 23,017.7 25,398.3 16,929.5
  40 ≤ age < 50 41,022.2 21,823.5 21,080.3 15,245.2
  50 ≤ age < 60 48,486.4 21,277.6 26,077.1 19,335.1
  ≥ 60 51,116.8 20,017.9 33,827.1 22,827.8
 Insurance types < 0.001
  UEBMI 44,956.4 23,994.1 25,292.3 18,410.2
  URBMI 43,002.9 19,858.8 23,070.2 15,460.2
 Hospital levels < 0.001
  Primary 19,764.9 15,675.1 7008.4 4565.4
  Secondary 32,083.2 16,919.9 18,638.6 12,948.4
  Tertiary 51,104.2 21,765.7 26,117.8 17,952.6
 Length of stay (days) < 0.001
  Days ≤ 100 10,540.1 7063.1 13,868.6 7311.2
  100 < days ≤ 300 33,104.6 14,617.7 37,037.8 13,515.9
  > 300 days 57,186.9 12,403.7 65,797.7 15,486.6
 Composition of inpatient costs < 0.001
  Laboratory and diagnostic costs 5537.7 7175.2 6141.0 6088.2
  Non-medication treatment costs 26,556.5 14,234.1 10,762.6 9275.5
  Medication costs 4775.9 3509.1 2756.9 2660.6
  Bed fees 7274.5 3446.4 3138.9 2511.5
 Inpatient costs 44,144.6 22,385.2 22,799.4 17,640.4 < 0.001
 Outpatient costs – – 1729.7 1546.2
 Total costs (inpatient + outpatient) 44,144.6 22,385.2 24,529.1 17,461.4 < 0.001
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Discussion
This is a retrospective 4-year cohort study conducted 
with a large schizophrenia sample in Guangzhou city, 
Southern China. We found that the average annual 
total direct medical costs for schizophrenia patient was 
CNY41,972.4 (US$6852.5) per capita in the baseline 
period, and increased to CNY56,544.1 (US$9231.5) at the 
end of the 3-year follow-up period. The inpatient costs 
remained as the key component of the total medical costs 
in 4  years. The type of insurance, age, higher hospital 
levels and longer LOS were significantly associated with 
inpatient costs. This is the first cohort study using sam-
ple from the claims database of an entire city to exam-
ine the direct medical costs of schizophrenia patients and 
compare the healthcare costs under two different urban 
insurance schemes in China.
When comparing our results with findings in other 
countries, we observed a large variation in costs. Our 
total direct medical cost (US$6852.5, 2014 price) was 
much lower than what have been reported in the United 
States (US$18,090, 2013 price [10]; US$21,672, 2011 
price [13]) and European countries, €12,251 (US$17,937, 
2008 price) [11] and €12,864 (US$16,141, 2006 price) 
[14] in Germany, €9507 (US$10,135, 2012 price) [12] in 
Switzerland, while it was higher than those reported in 
other Asian countries, such as and US$6594 (2015 price) 
[15] in Malaysia and US$274 [16] in India (all exchange 
rates drawn from the OECD Data). Although the interna-
tional comparison of per person costs for schizophrenia 
was restricted by different cost components (outpatient 
or inpatient services), data sources (claims or survey 
data), and estimation approaches (incidence-based or 
prevalence-based) included in those studies, the varia-
tion lies mostly in the health care systems across different 
countries.
In this study, the inpatient cost was the largest con-
tributor to the total direct medical costs for patients with 
schizophrenia, which was consistent with previous stud-
ies in other countries [14, 24, 25]. Patients presenting for 
the first time often showed acute psychotic symptoms 
that required hospitalization, while treatment for peo-
ple with repeated relapses was also still predominantly 
Table 5 Patients’ characteristics associated with inpatient costs (baseline period)
P-values are based on the Kruskal–Wallis test. All costs were based on a constant 2014 Chinese Yuan (CNY)
UEBMI Urban Employee Basic Medical Insurance scheme, URBMI Urban Resident Basic Medical Insurance scheme, SD standard deviation
Overall UEBMI URBMI P-value
Mean SD Mean SD Mean SD
No. patients n = 2971 n = 1760 n = 1211
Baseline (2010.11.01–2011.10.31)
 Gender < 0.001
  Female 38,472.3 23,410.4 38,225.7 24,643.4 38,890.5 21,176.9
  Male 43,930.2 22,323.1 45,357.4 23,775.3 42,049.3 20,111.6
 Age group < 0.001
  18 ≤ age < 30 25,980.9 19,092.7 23,158.9 20,005.9 27,520.1 18,478.7
  30 ≤ age < 40 31,455.8 22,309.1 28,033.2 24,000.3 34,181.0 20,517.0
  40 ≤ age < 50 38,191.0 22,310.9 36,502.7 24,097.8 40,059.8 20,013.3
  50 ≤ age < 60 46,378.2 22,167.3 46,652.1 23,057.3 45,724.8 19,910.5
  ≥ 60 50,470.3 20,403.9 50,308.8 21,999.6 50,812.8 16,559.9
 Hospital levels < 0.001
  Primary 18,457.3 15,537.7 15,274.6 13,706.2 23,077.3 17,052.0
  Secondary 31,244.4 17,065.9 31,131.6 17,767.6 31,394.8 16,104.8
  Tertiary 47,463.3 23,208.1 48,245.2 24,789.2 46,280.6 20,545.9
 Length of stay (days) < 0.001
  Days ≤ 100 10,904.7 7104.7 11,444.1 7441.7 9885.3 6308.5
  100 < days ≤ 300 33,705.9 14,388.3 35,683.3 15,101.7 30,357.1 12,429.8
  > 300 days 57,246.1 12,447.2 60,045.6 13,379.9 53,745.0 10,144.6
 Composition of inpatient costs < 0.001
  Laboratory and diagnostic costs 5604.5 7064.7 7447.3 7778.2 2926.2 4736.8
  Non-medication treatment costs 24,807.5 14,636.9 23,655.7 14,566.6 26,481.5 14,583.1
  Medication costs 4552.4 3483.3 4655.6 3665.6 4402.4 3195.3
  Bed fees 6816.5 3597.7 6616.5 3711.5 7107.2 3406.2
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hospital-based across the world [5]. The proportion of 
costs attributed to inpatient care varied from country to 
country, depending on the organization of mental health 
services [5]. Regarding the cost composition, the non-
medication treatment costs occupied the biggest propor-
tion of inpatient costs for schizophrenia patients, which 
included modified electroconvulsive therapy [26], tran-
scranial magnetic stimulation therapy [27], recreational 
therapy [28], individual psychotherapy [29], and group 
psychotherapy [30] during hospitalization. The medi-
cation costs were found to be the smallest part (10.9%) 
for inpatients. This percentage of medication costs was 
found to be lower than 14% in Switzerland [12] and 16% 
in France [31], but higher than 7% in Netherlands [32]. 
The medication percentages varied between countries, 
since differences reflected the structure of services, 
national pricing policies, the extent and methods of dis-
aggregation of costs, and the market share of the more 
expensive atypical antipsychotics [5]. When comparing 
schizophrenia costs to non-schizophrenia costs, a previ-
ous study in China indicated that among the schizophre-
nia patients, schizophrenia-related costs accounted for 
62% of all-cause costs per patient [18].
It is difficult to compare the average annual direct 
medical costs of schizophrenia per patient reported in 
this study to the other three China-based studies: Wu 
et  al. [18] reported that the mean direct medical costs 
of patients with schizophrenia were US$2863 (2009 
price) in Tianjin city, while US$862.81 (2010 price) was 
presented by Zhai et  al. [19] and US$1539 (2010 price) 
by Yang et al. [20]. Yang et al’s. [20] study reported only 
inpatient costs per admission, instead of annual costs 
per patient. The studies from Wu et  al. [18] and Zhai 
et  al. [19] included only 60.8% and 52.2% hospitalized 
patients, whilst all samples from our study had inpatient 
care. Thus, our samples were more likely to be relapsed 
patients with severer conditions, which may incur higher 
annual expenditures than previous studies.
Fig. 1 Composition of inpatient costs for 4-year periods: UEBMI and URBMI. All costs were based on a constant 2014 Chinese Yuan (CNY). UEBMI 
Urban Employee-based Basic Medical Insurance scheme, URBMI Urban Resident-based Basic Medical Insurance scheme
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It is the first time to evaluate the differences in direct 
medical costs between two urban health insurance 
schemes. We found that the total direct medical costs 
and the percentage of reimbursement expenses out of 
inpatient costs for those covered by the UEBMI scheme 
were higher than those covered by the URBMI scheme, 
mostly because the UEBMI had a higher benefit level for 
its beneficiaries [33]. The panel regression analysis in this 
study suggested that the inpatient costs of schizophrenia 
were significantly higher for patients with the UEBMI 
scheme. There are three possible explanations for this 
finding. Firstly, those residents who were covered by 
the UEBMI scheme faced almost equivalent reimburse-
ment rates for services provided by all levels of medical 
institutions, suggesting a tendency that they would more 
likely to seek medical treatment at higher level of hospi-
tals and incurred higher expenditures [34]. Secondly, the 
UEBMI offered a more generous benefits with a higher 
reimbursement rate for many services, higher annual 
reimbursement ceiling, and more comprehensive ser-
vice coverage for its beneficiaries. On the other hand, 
the URBMI scheme provided neither adequate financial 
protection nor service coverage for enrolled patients, 
therefore deter the incentive to use more expensive ser-
vices among the URBMI beneficiaries [34]. Thirdly, com-
pared with the non-employed patients under the URBMI 
scheme, the UEBMI patients had higher ability to pay and 
might be willing to consume additional health services, 
which were not covered by the health insurance. The cur-
rent health insurance reform to consolidate the different 
Table 6 Factors associated with total inpatient costs (GEE Model) 
The Generalized Estimating Equations (GEE) model estimates are reported in the table
UEBMI Urban Employee Basic Medical Insurance scheme, URBMI Urban Resident Basic Medical Insurance scheme
*** p < 0.01, ** p < 0.05
Overall UEBMI URBMI
n = 2971 n = 1760 n = 1211
Coef. Std. err. Marginal effect Coef. Std. err. Marginal effect Coef. Std. err. Marginal effect
Follow-up years
 Baseline (reference group)
 First year 0.097*** 0.007 4964.3 0.081*** 0.010 4277.5 0.120*** 0.010 5885.0
 Second year 0.087*** 0.007 4443.3 0.075*** 0.010 3973.3 0.102*** 0.010 5027.3
 Third year 0.124*** 0.008 6356.6 0.126*** 0.011 6618.8 0.125*** 0.011 6135.1
Age
 18 ≤ age < 30 (reference group)
 30 ≤ age < 40 0.162*** 0.030 8280.9 0.223*** 0.057 11,751.0 0.115*** 0.035 5670.0
 40 ≤ age < 50 0.042** 0.018 2148.3 0.074** 0.034 3886.1 0.002 0.018 116.0
 50 ≤ age < 60 − 0.001 0.010 − 56.9 − 0.003 0.015 − 172.2 − 0.016 0.012 − 795.9
 ≥ 60 0.018** 0.008 900.3 0.028*** 0.010 1470.9 − 0.011 0.012 − 536.1
Gender
 Female (reference group)
 Male − 0.016 0.008 − 815.8 − 0.004 0.012 − 203.7 − 0.032*** 0.011 − 1565.8
Insurance type
 URBMI (reference group)
 UEBMI 0.103*** 0.008 5270.0 – – – – – –
Hospital levels
 Primary (reference group)
 Secondary 0.091 0.047 4655.8 0.179** 0.076 9423.8 0.0003 0.047 -14.1
 Tertiary 0.447*** 0.047 22,894.6 0.576*** 0.075 30,330.8 0.299*** 0.047 14,701.1
Length of stay (days)
 Days ≤ 100 (reference group)
 100 < days ≤ 300 1.161*** 0.019 59,471.0 1.155*** 0.025 60,862.5 1.165*** 0.029 57,349.4
 > 300 days 1.707*** 0.017 87,481.9 1.705*** 0.022 89,848.1 1.714*** 0.025 84,387.9
Wald  chi2 17,506.97 9853.84 8309.63
P-value < 0.0001 < 0.0001 < 0.0001
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social health insurance schemes will facilitate the elimi-
nation on the disparities in benefit designs across health 
insurance schemes in financing and reimbursement [8].
Results from the regression analysis found that after 
controlling for other confounding variables, the asso-
ciation between age and total annual inpatient costs was 
non-linear, with the 30–40  years old patients had the 
highest costs. Particularly, the pattern in the differences 
in medical costs across age categories was quite different 
between UEBMI patients and URBMI patients. This sug-
gested that the management of costs for schizophrenia 
patients depending on a category of age might be imple-
mented differently across different insurance schemes. 
Variations in the costs of schizophrenia tend to be driven 
by the level of hospital, with patients having medical 
treatment in tertiary hospitals, being more likely to incur 
higher inpatient costs [35, 36]. Tertiary hospitals in China 
are often better equipped. Those advanced diagnostic 
and medical facilities might cause higher charges in ter-
tiary hospitals than in primary and secondary hospitals 
in spite of more precise diagnosis and better medical ser-
vice provided.
The positive association between the LOS and the 
hospitalization costs of schizophrenia is consistent with 
previous studies [35, 37]. In the present study, the mean 
annual LOS per patient was 254.7  days. It was longer 
than previous studies in United Kingdom (138.9  days) 
[37], South Korea (128  days) [38], or some other coun-
tries (11.1–47.2  days) [39–41]. The LOS of this study 
was also greater than that (112.1 days) in another China-
based study in Tianjin city [18]. It should be noted that it 
is difficult to directly compare the average annual LOS in 
this study with above literature since in those studies, the 
average LOS per admission was reported. Since patients 
who required a hospital admission associated with a 
diagnosis of schizophrenia were more likely to have 
relapsed [14, 42], and the costs of relapse were mainly 
due to hospital stay [43], our LOS per patient includ-
ing several admissions would be much longer. To better 
measure the disease burden of schizophrenia (and taking 
into account that the schizophrenia patients had multiple 
admissions within a year), the annual LOS per patient is a 
better indicator.
In addition, the longer LOS for schizophrenia patients 
might be due to the reimbursement fee schedule insti-
tuted by two urban health insurance schemes in China. In 
the case of psychiatric hospitalization for the UEBMI and 
URBMI enrollees, a fixed per diem cost of around US$30 
from the insurance fund is paid for the supplies without 
limitation of LOS [44]. Thus, the hospitals have incentive 
to extend LOS and increase inpatient admissions [44]. In 
addition, this study found that most of the schizophrenia 
patients had used inpatient care exclusively with more 
acute episodes, could also partly explain the long LOS. 
The findings of this study suggested that strategies to 
reduce hospitalization rates and LOS might be an effec-
tive method to contain the costs of schizophrenia. Cur-
rently, China has limited community psychiatric centers 
and many hospitals rarely provide services for schizo-
phrenia patients in the outpatient sector [18]. The longer 
inpatient stays in China may reflect fewer available com-
munity-based treatment options [7]. Previous studies in 
other countries indicated that community-based pro-
grams were effective to lower hospitalization rates among 
psychiatric patients, and they can divert patients from 
inpatient care to community-based treatment [45, 46]. 
A survey in 50 low- and middle-income countries sug-
gested that people with schizophrenia in low- and mid-
dle-income countries had limited access to specialized 
mental health services, and inpatient mental health facili-
ties only modestly contributed to overall service acces-
sibility [47]. This study showed that specialized mental 
health services alone were unable to cope with the bur-
den of schizophrenia in low- and middle-income coun-
tries, while primary care services should fill this gap by 
delivering effective packages of care in collaboration with 
specialized services [47]. Therefore, efforts to increase 
usage of community-based treatment programs and 
psychosocial rehabilitation for schizophrenia patients in 
China, may reduce the high costs and overuse of medical 
resources in the hospitals as well as the burden of health 
insurance funds.
Limitations
There were some limitations in this study. First, this study 
only analyzed direct medial costs. The indirect costs due 
to loss of productivity and family members’ informal care 
were not examined. Thus, we likely underestimated the 
total medical expenditures of schizophrenia in China. 
Second, clinical severity of the disease, disease dura-
tion, comorbidities and personal income levels, which 
were important predictors of costs, were omitted from 
the analysis because such data were not available in the 
claims dataset. Third, the study population was limited to 
urban enrollees under two insurance schemes in one city 
of China, which cannot generalize to the whole Chinese 
population. Further studies could consider more associ-
ated factors, indirect costs for a more comprehensive 
evaluation of schizophrenia costs and compare the schiz-
ophrenia costs to non-schizophrenia costs to evaluate the 
impact of health insurance.
Conclusions
The direct medical costs of schizophrenia were high and 
varied by types of insurance in China. The findings of this 
study provide vital information to understand the burden 
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of schizophrenia in China. Such information can also 
be used by decision makers in program evaluation and 
health resources allocation.
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